#HIKAL Q4FY23 Concall
1. Animal Health division to scale up in 18-24 months.
2. H2FY24 > H1FY24, They are expecting challenging H1FY24.
3. Expecting to commercialize 2 molecules in Pharma CDMO this year. Currently the molecules are in Phase 3. (1/n)
1. Animal Health division to scale up in 18-24 months.
2. H2FY24 > H1FY24, They are expecting challenging H1FY24.
3. Expecting to commercialize 2 molecules in Pharma CDMO this year. Currently the molecules are in Phase 3. (1/n)
4. R&D Expense will be about 3.5-4% of revenue.
5. Expecting tough H1 due to higher inventory lying with the partners in Agro division.
6. H1FY24 > H1FY23 - It is obvious 😀.
7. Expecting better margin from H2 onwards due to improved product mix. FY24 margins to be better. (2/n)
5. Expecting tough H1 due to higher inventory lying with the partners in Agro division.
6. H1FY24 > H1FY23 - It is obvious 😀.
7. Expecting better margin from H2 onwards due to improved product mix. FY24 margins to be better. (2/n)
8. Capex 200 Cr will be spent in Animal Health + Agro Division ramp up in Panoli and maintenance. No new capex announcement.
Based on the concall, I believe the growth triggers are still few quarters away. (n/n)
Based on the concall, I believe the growth triggers are still few quarters away. (n/n)
Loading suggestions...